Drug Approval | June 24, 2022
ANI Pharmaceuticals gets FDA approval of Clorazepate Dipotassium Tablets USP
ANI’s Clorazepate Dipotassium Tablets are the generic version of the Reference Listed Drug (RLD) Tranxene.
ANI’s Clorazepate Dipotassium Tablets are the generic version of the Reference Listed Drug (RLD) Tranxene.
U.S. FDA has issued Form 483 with six observations after an inspection of the company’s formulation manufacturing facility based out of Baddi
Ex-Azithromycin has shown a growth of 8% and 14% in April 2022 and May 2022 respectively
The company is strategically expanding its product portfolio with a pipeline of new products that will form a strong foundation for future growth.
Becomes the first airline globally to develop and launch sustainable, temperature-controlled containers for the transportation of pharmaceuticals
New milestone in the establishment of super-trillion antibody libraries for antibody discovery of challenging targets
The company has posted net profit of Rs.165.66 crores for the Financial Year ended March 31, 2022
Operations at Oakville, Canada manufacturing plant expected to end by first quarter 2023
Taiyin Yang, PhD, Executive Vice President, Pharmaceutical Development and Manufacturing to Retire After 29 Years at Gilead
Facility features LED lighting, solar panels, automation and innovative temperature-controlled systems to maximize efficiency and minimize environmental impact
Subscribe To Our Newsletter & Stay Updated
